World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Keith Berelowitz, MSc
Director of Operations

A scientist by training, Keith has worked in clinical research (academic and commercial) for over 22 years, having spent the majority of that period working for Richmond Pharmacology. In his role as Director of Operations at Richmond Pharmacology he is focused on the commercial management of the studies we conduct, the efficiency of the company’s functions and oversight of the healthy volunteer and patient recruitment division, integral to the studies conducted by Richmond Pharmacology.

Having played an operational role in over 250 studies, across the commercial, project and recruitment related management of these studies, his specialist area of interest has focused on the assessment and delivery of early and late phase patient trials in a Phase I environment. Keith has worked with a number of sponsors advising them on the viability of conducting such trials within the UK, a number of which have gone on to be conducted successfully with Richmond Pharmacology.

Keith is a member of the National Research Ethics Service Phase 1 Advisory Group (Health Research Authority, UK), Vice Chair of the Fulham Research Ethics Committee and a member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK) and one of the UK representative of the EUCROF Extended Executive Board

Back to experts

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more

Richmond Pharmacology supports Codiak BioSciences in the development of a new medicine to help patients with cutaneous T cell lymphoma.

February 3, 2021
Richmond Pharmacology were pleased to provide our sponsor, Codiak BioSciences, with positive results of its exosome therapeutic exoIL-12.
Read more

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more